NASDAQ:CFRX - ContraFect Corporation
$0.49
 $0.01
+2.16%
4:00PM EDT
2019-07-15
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CFRX     avg for
industry  
  avg for
sector  
42 stocks weight:  7. 10   114. 77   204. 78  
42 stocks rank:  4. 09 K 1. 44 K 810. 33  
# analyst opinions:  4. 00   13. 59   13. 86  
mean recommendation:  1. 70   2. 12   2. 04  

quick ratio:  4. 00   5. 48   1. 89  
current ratio:  4. 23   5. 85   2. 40  

target price low:  0. 35   82. 72   115. 11  
target price avg:  0. 48   104. 42   138. 02  
target price high:  0. 68   130. 64   159. 47  
1-yr high:  2. 59   110. 27   142. 72  
last close:  0. 48   85. 12   126. 54  
50-day avg:  0. 48   86. 06   122. 35  
200-day avg:  1. 01   88. 76   121. 75  
1-yr low:  0. 36   69. 26   100. 63  
volume:  158. 64 K 3. 51 M 5. 53 M
50-day avg volume:  652. 94 K 3. 21 M 4. 22 M
200-day avg volume:  792. 45 K 3. 04 M 4. 75 M

1-day return:  -3. 45 % -0. 30 % -1. 01 %
this week return:  -10. 02 % -2. 16 % -1. 35 %
12-wk return:  -10. 36 % 3. 34 % 8. 69 %
52-wk return:  -82. 08 % -1. 76 % 12. 22 %

enterprise value (EV):  23. 00 M 46. 50 B 123. 99 B
market cap:  37. 80 M 40. 77 B 109. 11 B
EBITDA:  -30. 34 M 4. 33 B 8. 19 B
enterprise multiple (EV/EBITDA):  -0. 76   5. 45   12. 05  
total debt:  4. 09 M 11. 27 B 17. 58 B
debt/equity:  23. 38   57. 36   120. 25  
net income (common):  -6. 99 M 2. 13 B 4. 27 B

shares outstanding:  79. 41 M 551. 08 M 1. 24 B
shares:  58. 03 M 559. 41 M 1. 22 B
shares short:  568. 57 K 11. 15 M 11. 94 M
shares short prior month:  554. 74 K 9. 31 M 11. 96 M
short ratio:  0. 50   5. 72   3. 43  
short % of float:  0. 80 % 6. 40 % 2. 65 %
total cash/share:  0. 29   11. 00   9. 23  
total cash:  23. 09 M 6. 03 B 6. 01 B
free cash flow:  -16. 38 M 3. 02 B 4. 96 B
operating cash flow:  -26. 77 M 3. 92 B 5. 99 B

book value:  0. 22   13. 02   27. 49  
price/book:  2. 16   4. 21   8. 80  
gross profits:  -684. 28 K 7. 67 B 36. 29 B
operating margins:  0. 00 % -380. 20 % -38. 44 %
EBITDA margins:  0. 00 % 13. 59 % 23. 24 %
profit margins:  0. 00 % 10. 94 % 14. 00 %
gross margins:  0. 00 % 36. 11 % 55. 16 %

1-yr max volatility:  54. 62 % --- ---
1-yr mean volatility:  4. 18 % 1. 50 % 1. 08 %

1-yr EPS:  -0. 09   2. 12   4. 26  
forward EPS:  -0. 35   3. 47   7. 14  
P/E:  -5. 29   2. 15   33. 17  
forward P/E:  -1. 39   -4. 03   17. 60  
PE/G:  0. 44   0. 54   0. 34  
growth:  -12. 14 % 263. 03 % 78. 34 %
earnings high:  -0. 08   0. 91   1. 70  
earnings avg:  -0. 09   0. 71   1. 58  
earnings low:  -0. 09   0. 48   1. 46  
revenue high:  -0. 00   2. 64 B 11. 26 B
revenue avg:  -0. 00   2. 58 B 11. 09 B
revenue low:  -0. 00   2. 54 B 10. 90 B
return on assets:  -52. 15 % -2. 31 % 5. 31 %
return on equity:  -46. 61 % -82. 48 % 135. 30 %

beta (1yr vs S&P500):  0. 05   1. 26   0. 91  
sharpe (1yr):  -0. 94   0. 07   0. 77  

held % insiders:  7. 63 % 6. 08 % 3. 31 %
held % institutions:  55. 70 % 78. 36 % 69. 61 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-14 : CFRX
.     100.79 =        100.79 :: --> INITIAL WEIGHT <--
.     - 0.09 =         100.7 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.091 =       210.583 :: P/E factor
.    x 1.231 =       259.199 :: PE/G factor
.    x 1.437 =       372.412 :: beta factor
.    x 0.978 =        364.21 :: sharpe factor
.    x 2.723 =       991.665 :: current ratio factor
.    x 1.155 =      1145.267 :: quick ratio factor
.    x 1.787 =       2046.57 :: short ratio factor
.    x 1.011 =      2068.592 :: price-to-book factor
.    x 1.186 =      2454.241 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.114 =      5188.227 :: sector+industry 1-year gains factor
.    x 1.033 =      5361.503 :: industry 12-weeks return factor
.    x 1.305 =      6998.229 :: industry 2-weeks return factor
.     x 1.11 =      7769.991 :: 5-day avg > 50-day avg
.    / 2.157 =      3602.821 :: overall "drift" factor
.    x 0.672 =      2421.024 :: largest single-day jump factor
.     x 0.06 =       144.937 :: low price factor
.    x 0.714 =       103.516 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.     x 0.35 =        36.231 :: forward EPS factor
.    x 0.764 =        27.673 :: forward P/E factor
.    x 1.182 =        32.722 :: industry recommendation factor
.    x 2.442 =        79.894 :: company recommendation factor
.    x 1.008 =        80.505 :: factor historical industry gain for week 28
.    x 0.921 =        74.183 :: target low factor
.    x 1.018 =        75.555 :: target mean factor
.    x 1.027 =        77.622 :: target high factor
.    x 9.158 =         710.9 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =         5.164 :: reduced for readability
.     + 1.94 =         7.104 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                      7.104 :: FINAL WEIGHT for NASDAQ:CFRX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org